Celcuity (NASDAQ:CELC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Celcuity (NASDAQ:CELC) from a sell rating to a hold rating in a report published on Saturday morning.

CELC has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $70.00 target price on shares of Celcuity in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. Stifel Nicolaus assumed coverage on Celcuity in a report on Tuesday, July 1st. They issued a “buy” rating and a $30.00 price target for the company. HC Wainwright upped their price objective on shares of Celcuity from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Monday, August 18th. Finally, Leerink Partners upped their price objective on shares of Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, July 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and an average price target of $62.75.

Celcuity Stock Performance

CELC opened at $70.58 on Friday. The stock has a market cap of $2.99 billion, a P/E ratio of -20.46 and a beta of 0.70. The company has a debt-to-equity ratio of 2.24, a current ratio of 4.58 and a quick ratio of 4.58. The stock’s 50 day simple moving average is $52.25 and its 200 day simple moving average is $28.12. Celcuity has a 1-year low of $7.57 and a 1-year high of $83.00.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). As a group, equities analysts anticipate that Celcuity will post -2.62 EPS for the current fiscal year.

Insider Activity at Celcuity

In other Celcuity news, Director David Dalvey sold 100,000 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director owned 125,000 shares of the company’s stock, valued at $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 15.78% of the company’s stock.

Hedge Funds Weigh In On Celcuity

Large investors have recently bought and sold shares of the business. Trexquant Investment LP lifted its holdings in Celcuity by 131.3% in the first quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock worth $272,000 after acquiring an additional 15,280 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in Celcuity by 59.0% in the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock worth $43,046,000 after acquiring an additional 1,579,182 shares during the last quarter. Rhumbline Advisers lifted its holdings in Celcuity by 8.9% in the first quarter. Rhumbline Advisers now owns 42,194 shares of the company’s stock worth $427,000 after acquiring an additional 3,439 shares during the last quarter. Nuveen LLC bought a new position in Celcuity in the first quarter worth about $704,000. Finally, GAMMA Investing LLC lifted its holdings in Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock worth $131,000 after acquiring an additional 1,225 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.